CD274 and hepatocellular carcinoma: Immunotherapy is the most recent therapeutic option for HCC, such as nivolumab and pembrolizumab, which are used to treat advanced HCC patients by preventing the immune checkpoint inhibitor PD-1 from interacting with its ligands, PD-L1; T lymphocytes are subsequently activated to achieve antitumor effects [9].